Nektar Therapeutics (NKTR) is a publicly traded Healthcare sector company. As of July 21, 2026, NKTR trades at $69.55 with a market cap of $2.19B and a P/E ratio of -8.26. NKTR moved +5.93% today. Year to date, NKTR is +62.42%; over the trailing twelve months it is +177.01%. Its 52-week range spans $6.48 to $109.00. Analyst consensus is strong buy with an average price target of $154.33. Rallies surfaces NKTR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for NKTR, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $69.55 |
| Market Cap | $2.19B |
| P/E Ratio | -8.26 |
| EPS | $-8.23 |
| Dividend Yield | 0.00% |
| 52-Week High | $109.00 |
| 52-Week Low | $6.48 |
| Volume | 761.75K |
| Avg Volume | 0 |
| Revenue (TTM) | $55.63M |
| Net Income | $-158.10M |
| Gross Margin | 0.00% |
8 analysts cover NKTR: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $154.33.